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1. Introduction
SUMOylation is an ATP-dependent post translational modification where a small ubiquitin-
like modifier (SUMO) protein is covalently bound to a lysine residue in target proteins 
exhibiting a SUMO-interaction motif, ΨKXE/D, Ψ being a large hydrophobic amino acid 
[73]. Similar to ubiquitination, SUMO conjugation is achieved by different enzymes, E1-
activating (SAE1/UBA2 complex), E2-conjugating (Ubc9) and various E3-ligases.
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SUMOylation has been described in numerous cellular processes including nuclear-cytosolic 
transport, transcriptional regulation, apoptosis, protein stability, response to stress, and 
progression through the cell cycle [33], and is an important regulator of neuronal and 
synaptic function [34]. SUMO targets several cytosolic and plasma membrane proteins, 
including ion channels, to regulate plasma membrane depolarization or neurotransmission 
by modulating their stability, sub-cellular targeting, transport or interacting properties [53; 
54; 72].
Collapsin response mediator protein 2 (CRMP2), is a tetrameric protein which specifies 
axon/dendrite fate and axonal outgrowth [37; 42], and was shown, using sequence alignment 
and structure analysis, to be SUMOylated on Lysine 374 [20]. We demonstrated that 
SUMOylation of CRMP2 at site 374 is dependent on phosphorylation at Serine 522 by 
cyclin-dependent kinase 5 (Cdk5) [19], which is thought to disrupt CRMP2 tetramer towards 
a monomeric state, thus exposing the SUMOylation site [20].
SUMOylation of CRMP2 specifically controls trafficking and surface expression of the 
tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channel NaV1.7 [10; 19; 21]. 
Decreasing CRMP2 SUMOylation, using CRMP2 mutants with disrupted SUMO motifs, 
reduced NaV1.7 currents. As inferred from human pain disorders, NaV1.7 is a major 
contributor to nociception and pain signaling. Gain-of-function mutations in NaV1.7 
increase neuronal excitability and underlie pain disorders whereas loss-of-function 
mutations render individuals insensitive to painful stimuli [14; 24; 83; 91]. The potential of 
targeting NaV1.7 in pain is highlighted by many patents filed and clinical trials being 
conducted (see [23]). As pan NaV1.x blockers have a potent analgesic effect, there is a vital 
need for NaV1.7-specific treatment, which is lacking in many NaV1.7 drug-development 
programs.
Targeting NaV1.7 indirectly, but specifically, via modulation of CRMP2 SUMOylation has 
been demonstrated to be a promising avenue for experimental neuropathic pain treatment 
[64]. In the chronic model of spared nerve injury (SNI), CRMP2 SUMOylation was 
increased, and reducing deSUMOylation of CRMP2, by expressing CRMP2 K374A in vivo, 
significantly reversed SNI mechanical allodynia [64]. Consequently, we postulated that (i) 
CRMP2 interacts with Ubc9 and (ii) disruption of this interaction using a CRMP2 SUMO 
peptide would specifically reduce NaV1.7 sodium current, resulting in a relief of 
neuropathic pain [10].
Here, we assessed binding between the Ubc9 E2 SUMO-conjugating enzyme and CRMP2 
using microscale thermophoresis and determined that CRMP2 and Ubc9 interact directly 
and with low micromolar affinity. Using rational design, we identified a heptamer peptide 
containing the CRMP2 SUMOylation consensus site fused to the transduction domain of the 
HIV-1 tat protein, called t-CSM, to disrupt the CRMP2-Ubc9 interaction. This t-CSM 
peptide inhibited CRMP2 SUMOylation, NaV1.7 membrane trafficking, and specifically 
inhibited NaV1.7 sodium influx in sensory neurons. Intrathecal injection of t-CSM reversed 
nerve injury-induced thermal and mechanical hypersensitivity with no sedation or motor 
impairment in rats.
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2. Methods
2.1. Animals
Adult male and female Sprague-Dawley rats (Pathogen-free male 250–275 g, female 200–
225 g, Envigo, Placentia, CA) or female mice (C57BL/6NHsd, 20–24 g; Envigo) were kept 
in light (12-h light: 12-h dark cycle; lights on at 07:00 h) and temperature (23 ± 3°C) 
controlled rooms. Standard rodent chow and water were available ad libitum. University of 
Arizona’s College of Medicine Institutional Animal Care and Use Committee (IACUC) 
approved these protocols. All experiments were performed congruent with the National 
Institutes of Health’s Guide for Care and Use of Laboratory Animals and per the ethical 
guidelines reported by the International Association for the Study of Pain. Treatment and 
control groups consisted of randomly assigned animals and experimenters were blinded to 
the grouping information until the analysis was completed.
2.2. Materials
The CRMP2 SUMOylation Motif (CSM) peptide chemically linked to the cell-penetrating 
motif (CPP) of the HIV transactivator of transcription peptide tat (t-CSM; 
YGRKKRRQRRRGKMDENQ; tat sequence identified by the underlined text) was 
manufactured and HPLC-purified by Genscript USA Inc. (Piscataway, NJ) and was 
resuspended in double-distilled water or DMSO (Sigma-Aldrich, St. Louis, MO), aliquoted, 
and stored at −20°C. Several of our studies previously showed the lack of effect of both 
scramble and random peptides fused with different CPPs in both in vitro and in vivo studies 
[4; 26; 40; 70]. All chemicals, unless stated otherwise, were purchased from Sigma-Aldrich. 
Fura-2 Low Affinity and Sodium-binding Benzofuran Isophthalate Acetoxymethyl ester 
(SBFI-AM) was obtained from Teflabs (Austin, TX). Catecholamine A differentiated (CAD) 
(ECACC Cat# 08100805) cells, of mouse origin, were grown in cell culture conditions at 
37°C in 5% CO2. CAD cells were grown in DMEM/F12 media supplemented with 10% 
FBS (Hyclone) and 1% penicillin/streptomycin sulfate from 10,000 μg/ml stock. CAD cells 
were chosen as a model neuron cell line due to ~80% contribution by NaV1.7 to total 
sodium currents as determined by isoform-specific blockade of NaV1.7 by both ProTox-II 
(Sigma, St. Louis, MO) and Huwentoxin-IV (Alomone Laboratories, Jerusalem, Israel) [20; 
21].
2.3. Co-immunoprecipitation and immunoblotting
Co-immunoprecipitation experiments were performed on spinal cord lysates from adult 
Sprague-Dawley rats using lysates homogenized in RIPA buffer as described previously 
[26]. Samples were then processed by immunoblotting as described [4; 5]. Blots were 
probed with anti-Ubc9 (Catalogue# ab21193, Abcam), or anti-CRMP-2 (Catalogue# 2993, 
Sigma-Aldrich) (both 1:1000). At least three blots were done per experiment.
2.4. Purification of recombinant human CRMP2-His and Ubc9-GST
Recombinant human CRMP2-His was expressed and purified as described previously [26]. 
The pure CRMP2 protein was concentrated to 30 mg/mL, flash frozen in liquid nitrogen and 
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stored at −80°C. Ubc9-GST fusion protein was expressed and purified as previously 
described in [30].
2.5. Microscale Thermophoresis (MST)
MST, an assay that monitors the thermophoretic movement of molecules in optically 
generated microscopic temperature gradients thereby permitting analysis of biomolecular 
interaction was performed as described previously [86; 87]. In MST, increasing 
concentrations of unlabeled ligand are mixed with the fluorescently labeled biomolecule 
which is kept at a constant concentration. Purified CRMP2-His was fluorescently labelled 
with a His-Tag labeling kit RED-Tris-NTA (Nanotemper, Germany) per manufacturer’s 
instructions. Two hundred nanomolar of CRMP2-His (in PBS supplemented with 0.05% 
Tween-20 (PBS-T buffer)) was mixed with 1M NT-647-His-labeling dye. After a 30 min 
incubation at room temperature, the labeled CRMP2 was pelleted by centrifugation at 
15,000Xg for 10 min at 4°C. 50 nM of NT-647-CRMP2 was mixed with different 
concentrations of Ubc9-GST in PBS-T and incubated at room temperature for 10 min. The 
thermophoresis readouts were captured on a Monolith NT.115 (Nanotemper, Germany) 
using premium MST capillaries, at 40% LED and 40% MST power. Measurements were 
done in triplicates. Data analysis was performed with the MO Affinity Analysis software 
(Nanotemper) using the Kd model (standard fitting model derived from law of mass action).
2.6. Ubc9-CRMP2 interaction measured by amplified luminescent proximity homogeneous 
alpha assay (ALPHA)
ALPHA experiments were performed per instructions supplied by PerkinElmer (USA). 
After a first mix of 200 nM of Ubc9-GST with 800 nM CRMP2-GST, 10 μL of donor and 
15 μL acceptors beads (both at 10mg/mL) were added and incubated for one hour. The 
reaction was read at an emission wavelength of 615 nm using an excitation wavelength of 
680 nm, on a PerkinElmer EnVisionTM plate reader.
2.7. Immunoprecipitation (IP) of endogenously SUMOylated proteins and CRMP2 from cell 
lysate
CAD cells, treated with 20 μM t-CSM peptide (or control, i.e. 0.01% DMSO) overnight, 
were lysed into the immunoprecipitation buffer exactly as previously described [11]. 
Immunoblotting was performed with a anti-CRMP2 antibody (Catalogue #2993, Sigma) on 
samples immune-captured by immunoprecipitation with a SUMO1 antibody (Catalogue 
#S8070, Sigma, St. Louis, MO).
2.8. Patch clamp electrophysiology
Whole cell voltage clamp recordings were performed at room temperature on CAD cells 
using an EPC 10 Amplifier (HEKA Electronics, Germany) exactly as described previously 
[20; 21].
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2.9. Primary dorsal root ganglion (DRG) neuronal cultures
DRGs from all levels were acutely dissociated using methods as described previously [26]. 
Rat DRG neurons were isolated from Sprague-Dawley rats using previously developed 
procedures [26; 63].
2.10. Sodium fluorescence imaging
Sodium fluorescence imaging of rat cultured DRG neurons grown for 4 days in vitro (4 
DIV) was performed exactly as described before [6]. Changes in cytosolic Na+ 
concentration ([Na+]c) were examined using the Na+-sensitive dye SBFI-AM (Molecular 
Probes, Eugene, OR). Neurons were loaded with 9 μM SBFI-AM for 1 hour at 37ºC. [Na+]c 
was calculated using equations [32] as described previously [16], assuming a dissociation 
constant of 15.7 mM for SBFI.
2.11. NaV1.7 surface staining
DRG neurons in culture were treated with either 20 μM of t-CSM or 0.1% DMSO overnight. 
The neurons were washed in ice-cold PBS twice before incubation (40 min) with anti-
NaV1.7 antibody (extracellular epitope, dilution 1/40, Cat# ASC-027, Alomone labs, Israel) 
for ice. Cells were washed in ice-cold PBS thrice before fixation with 4% paraformaldehyde 
(10 min, 4°C). The neurons were next kept in blocking buffer (BSA (3% w/v) in PBS) for 20 
min at room temperature (RT) before addition of the (goat anti rabbit Alexa Fluor 488 
secondary antibody (Catalogue # A-11008, Thermofisher) for 1 hour at RT. After 3 washes 
with PBS, the coverslips were fixed and imaged with a Nikon Eclipse Ti-U (Nikon 
instruments) using a Photometrics cooled CCD camera CoolSNAPES2 (Roper Scientific, 
Tucson, AZ) run by Nis Elements software (version 4.20, Nikon Instruments). The 
fluorescence intensity for each cell was quantified and normalized to the area of the region 
of interest using NiS elements software. To obtain the region of interest, the perimeter of 
each neuron was manually traced.
2.12. Spared nerve injury model of neuropathic pain
The biceps femoris muscle was dissected to bare the 3 terminal branches of the sciatic nerve 
to create the spared nerve injury as described previously [15]. Sham animals also underwent 
the same operation; however, the nerves were exposed and not ligated. Before any testing, 
animals were allowed to recover for 5–7 days.
2.13. Indwelling intrathecal catheter
Rats were sedated using a xylazine/ketamine/ (12/80 mg/kg intraperitoneal; Sigma-Aldrich) 
and placed in a stereotaxic head holder. Following the exposition and incision of the cisterna 
magna, an 8-cm catheter (PE-10; Stoelting) was implanted as previously reported [89].
2.14. Testing of allodynia
The assessment of tactile allodynia was done exactly as reported before using the “up and 
down” method described before [9]. Data were expressed as the mean withdrawal threshold.
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2.15. Writhing test
The acetic acid-induced writhing test is a model of visceral pain where a chemical irritant -
acetic acid- is injected intraperitoneally, inducing abdominal contractions and extension of 
back limbs, collectively defined as ‘writhes’ [55]. Animals were first allowed to acclimate 
with the clear Plexiglas chamber used for the experiment during 15 min or until explorative 
behavior ceased. Mice were then immediately injected in the peritoneum of the left lower 
quadrant of the abdomen with 300 μl of 1% acetic acid in normal saline, via a 27-gauge 
needle. After the acetic acid injection, mice were placed in the testing chamber and their 
subsequent nociceptive behavior was recorded and scored (in an investigator blinded 
manner): writhing behavior was assessed between 5 and 25 min after the injection. t-CSM 
peptide (4 μg or the vehicle 0.1% DMSO in the control group) were administered i.t. (in a 
volume of 10 μl), 60 min before the acetic acid injection.
2.16. Rotarod
A week after surgical placement of the intrathecal catheters, the rats were trained and then 
assessed (every 30 min for 3 hours) for their capability to stay on a rotating rod following 
intrathecal delivery of peptide (or vehicle) as described before [71]. For SNI rats training 
consisted of 2 training sessions on a non-rotating rotarod followed by 2 training sessions 
where the rotarod was set at 4 and 8 rpm respectively after intrathecal injection of t-CSM or 
vehicle as indicated. Testing was done on an accelerating rotarod (4 to 40 rpm, 5min) and 
repeated every half hour for the first hour after drug administration and every hour for 4 
more hours for a total of 5 hours.
2.17. Data Analysis
Statistical significance was determined using GraphPad Software (LaJolla, CA). Student’s t-
test or a one- or two-way ANOVA followed by post hoc comparisons (Dunnett’s or Tukey’s 
test) were used to assess the statistical significance of differences between means. Results 
were stated as significant when the corresponding P value was less than 0.05.
3. Results
3.1. Ubc9 interacts directly with CRMP2
We previously reported that the CRMP2 protein sequence has a canonical ψ-K-X-E/D 
SUMOylation motif which accommodates E2-conjugating enzyme Ubc9-mediated addition 
of SUMO [20; 21]. Here, we asked whether, during the course of SUMOylation, CRMP2 
interacts with Ubc9. In the present study, co-immunoprecipitation experiments revealed an 
interaction between Ubc9 and CRMP2 in CAD cells (Fig. 1).
Microscale thermophoresis (MST) was used to test if there is direct binding between 
CRMP2 and Ubc9 using purified recombinant proteins. In MST, an infrared laser generates 
precise microscopic heat gradients within capillaries containing a fluorescently labeled 
protein (i.e., CRMP2). The diffusion of labeled molecules along these temperature gradients 
is measured in the presence of ranging concentrations of an unlabeled ligand (Ubc9) [39; 
75]. As the concentration of Ubc9 increases, it binds to CRMP2 altering its thermodiffusion 
out of the heated infrared spot, resulting in a change in the MST signal and providing a 
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record of the binding between CRMP2 and Ubc9 (Fig. 2A). As a negative control, CRMP2 
was also incubated with various concentrations of GST; no association could be detected 
between GST and CRMP2 (Fig. 2B, C). NT647-labeled CRMP2 (100 nM) was mixed with 
varying concentrations of Ubc9 (0.003–100 μM) and apparent Kd values were calculated by 
fitting curves using the standard fitting model derived from law of mass action. The MST 
experiments revealed that Ubc9 binds to CRMP2 with an apparent Kd of 12.2 ± 2.7 μM (Fig. 
2C). ATP (1 mM), a necessary co-factor for the SUMOylation machinery, did not alter the 
affinity of the Ubc9/CRMP2 interaction (Fig. 2C). Divalent cations MgCl2 (200 mM) or 
CaCl2 (200 mM), believed to favor CRMP2 tetramerization [51], also did not alter the Kd 
values of the Ubc9/CRMP2 interaction (Fig. 2C). These results establish CRMP2 as a bona 
fide binding partner of Ubc9.
3.2. Rational design of a CRMP2 SUMOylation motif “decoy” peptide
We previously identified CRMP2 SUMOylation as a potential biomarker for neuropathic 
pain [64]. In rodents inflicted with a spared nerve injury (SNI) mimicking chronic pain, 
CRMP2 SUMOylation was found to be increased and preventing SUMOylation of CRMP2, 
by expressing the SUMO-null CRMP2 K374A in vivo, significantly reversed SNI-induced 
mechanical allodynia [64]. The sequence GKMDENQ (Fig. 3; SUMOylated lysine at 
position 374 underlined) in CRMP2 conforms to a canonical SUMOylation motif [84]. 
Reasoning that a peptide encompassing this region (CRMP2 SUMOylation motif (CSM)) 
could serve as a “decoy” and act as a sink for SUMOylation by Ubc9, we fused CSM to the 
cell penetrating transduction domain of the HIV-1 trans-activator of transcription (tat, t) 
creating the cell permeable peptide t-CSM. The resulting t-CSM peptide was incubated with 
Ubc9 to assess binding using MST (Fig. 3D), revealing an interaction with a Kd of 0.4 ± 0.1 
μM.
3.3. Inhibition of Ubc9-CRMP2 interaction using t-CSM peptide
Next, we tested if t-CSM peptide could inhibit the Ubc9-CRMP2 interaction. For this we 
initially turned to the amplified luminescent proximity homogeneous assay (ALPHA), a 
bead-based assay amenable to high throughput screening and miniaturization (Fig. 4A) [22]. 
Briefly, we incubated purified CRMP2-His protein bound to a Ni-chelate acceptor bead and 
Ubc9-GST protein bound by a glutathione-coated donor bead (Fig. 4B). If an acceptor bead 
comes into proximity with a donor bead, the acceptor bead emits a fluorescence signal 
between 520–620 nm. The donor bead contains a photosensitizer, phthalocyanine, that 
converts ambient oxygen to an excited singlet form of oxygen. This singlet oxygen will react 
with a thioxene derivative on the acceptor bead culminating in a chemiluminescent reaction. 
This reaction occurs only if the beads are within 200 nm of each other. The strength of the 
singlet oxygen reaction is also proportional to the amount of analyte present. In the absence 
of acceptor beads or any beads, no ALPHA signal was produced (Fig. 4C). Incubating 
various concentrations of Ubc9 (from 0.005 to 5 μM) with 1 μM CRMP2 which gave an 
apparent Kd of 0.8 ± 0.1 μM (Fig. 4D); this binding was stable over at least an 18 hr window. 
No binding could be detected between Ubc9 and CRMP2 in the presence of 10 μM t-CSM 
peptide; the data could not be fitted to a curve (r2 = 0.23) (Fig. 4D).
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To test if t-CSM could be useful in inhibiting the Ubc9-CRMP2 interaction, we performed 
MST analyses between CRMP2 and Ubc9 in the presence of increasing concentrations of t-
CSM. Ubc9-CRMP2 binding was reduced by t-CSM in a concentration-dependent manner: 
2.5 μM t-CSM reduced the binding of Ubc9-GST to CRMP2 (Kd = 80 ± 14 μM) while 5 μM 
t-CSM reduced it even further (Kd = 137 ± 14 μM, respectively) (Fig. 5). No association 
could be detected between CRMP2 and Ubc9 at 10 and 20μM of t-CSM (Fig. 5). In separate 
pull-down experiments with bacterially produced Ubc9-GST, CRMP2 binding to Ubc9 was 
also reduced by t-CSM in spinal cord lysates (data not shown). Collectively, these results 
show that the Ubc9-CRMP2 interaction can be recapitulated both with recombinant proteins 
and in native tissue and that t-CSM can interfere with this interaction.
3.4. t-CSM peptide decreases SUMOylation of CRMP2 in CAD cells
Having established that t-CSM can interfere with the Ubc9-CRMP2 interaction, we next 
sought to investigate whether cellular dialysis of t-CSM could prevent CRMP2 
SUMOylation. Since there is no known antibody that selectively identifies SUMOylated 
CRMP2, we performed the following experiment. We prepared lysates from CAD cells in a 
denaturing lysis buffer, then heat denatured them to completely unfold and disrupt non 
covalent protein complexes and to inactivate SUMO isopeptidases [88]; the mouse CAD 
(CNS catecholaminergic cells) neuronal cell line were chosen because they expresses high 
levels of NaV1.7 [81]. An immunoprecipitation was then performed with a SUMO1 
antibody followed by immunoblotting with a CRMP2 antibody to detect SUMOylated 
CRMP2. As shown in Fig. 6A–B, expression of a SUMO-null (K374A) CRMP2 or dialysis 
of the t-CSM “decoy” peptide decreased the amount of detectable SUMOylated CRMP2. 
These results demonstrate that endogenous CRMP2 SUMOylation is inhibited by the t-CSM 
peptide.
3.5. t-CSM peptide decreases Na+ currents in CAD cells
We previously reported that CRMP2-K374A, a non-SUMOylated mutant of CRMP2, 
impairs sodium current density in CAD cells [19; 21]. If preventing CRMP2 SUMOylation 
were achieved by cellular dialysis of t-CSM, then we would expect NaV1.7 current density 
to be diminished consistent with our published data. Current-voltage relationships in 
transfected CAD cells were recorded by the application of 5-ms step depolarizations ranging 
from −70 mV to +60 mV (in +5 mV increments) from a holding potential of −80 mV (Fig. 
7A). The transient inward current in CAD cells activated between −40 and −30 mV and 
reached its peak at 0 to +10 mV (Fig. 7B). Peak inward Na+ currents were measured and 
expressed as normalized peak current density to account for variations in cell size. Sodium 
currents were reduced to 42.5 ± 5.9% (n=6) in CAD cells treated with 20 μM of t-CSM 
compared to those treated with DMSO (0.1%) (Fig. 7C). There was no difference in 
Boltzmann parameters of voltage dependence of activation, half-activation voltage (V½), and 
slope factor (k) between the two treatment conditions (Fig. 7D).
3.6. t-CSM attenuates ouabain-induced increase in cytosolic Na+ in primary sensory 
neurons
The above data showing t-CSM peptide inhibits NaV1.7 currents (Fig. 8) is consistent with 
our published results demonstrating diminution of NaV1.7 currents in cells lines and in 
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sensory neurons expressing the SUMO-null CRMP2-K374A mutant [19–21]. 
Notwithstanding that conventional patch clamp remains the sole technique with sufficiently 
high time resolution and sensitivity required for precise and direct characterization of ion 
channel properties, it is universally accepted that patch clamp is a slow, labor-intensive, and 
thus expensive, technique. In anticipation of a future high throughput screening campaign 
for SUMOylation inhibitors of Ubc9 that we will likely identify in the ALPHA screen, we 
developed a low-to-medium throughput sodium fluorescence assay. Changes in cytolosolic 
Na+ ([Na+]c) were monitored using the Na+-sensitive fluorescent dye, SBFI-AM. Ouabain, 
an inhibitor of Na+/K+-ATPase, was used to increase [Na+]c, which was monitored using 
SBFI. Ouabain resulted in an increase in [Na+]c (Fig. 8A). Pre-treatment of neurons with t-
CSM (10 μM for 12 hours) strongly attenuated ouabain-induced increase in [Na+]c (Fig. 
8B). The ouabain-induced increase in [Na+]c was also inhibited by tetrodotoxin (TTX, 1 
μM), a pan-blocker of NaV1.1 to NaV1.7 channels [44], and Protox (10 μM), a specific 
blocker of NaV1.7 [74], suggesting that this increase in [Na+]c is mediated by voltage-gated 
Na+ channels and, specifically, by NaV1.7 (Fig. 8C, D). Ouabain-induced changes in [Na+]c 
over time were quantified by calculating the area under the curve (AUC) (Fig. 8E). Taken 
together, the data obtained with Protox and inhibition of ouabain-induced increase in [Na+]c 
by t-CSM suggest that this peptide reduces NaV1.7 function as well.
3.7. t-CSM peptide impedes membrane trafficking of NaV1.7 in DRGs
Next, we used immunofluorescent microscopy to determine if t-CSM affected the 
subcellular localization of NaV1.7. Sensory neurons were incubated with 20 μM t-CSM 
peptide and examined after live labeling of NaV1.7 with an antibody targeting an 
extracellular epitope of NaV1.7. Visual inspection of the micrographs (Fig. 9A) 
demonstrated that, in control cells treated with vehicle, the fluorescent signal for 
extracellular NaV1.7 appeared in the vicinity of the plasma membrane of the DRG neurons. 
As illustrated in Fig. 9A, prominent membranous NaV1.7 staining was observed in the 
absence of peptide (top panel) but significantly reduced in the presence of t-CSM (bottom 
panel). Quantification from 30–45 cells revealed an ~80% reduction in surface NaV1.7 (Fig. 
9B). Taken together, these results suggest that, t-CSM related inhibition of CRMP2 
SUMOylation prevents NaV1.7 from being targeted to the DRG neuronal membrane.
3.8. t-CSM peptide reverses neuropathic pain
Nav1.7 is upregulated and promotes ongoing pain in animal models of chronic peripheral 
inflammation and in peripheral nerve injury [43; 77]. Recently, we reported that (i) NaV1.7 
upregulation in chronic neuropathic pain is accompanied by a concomitant increase in 
CRMP2 SUMOylation, and (ii) loss of CRMP2 SUMOylation, mimicked by expressing a 
non-SUMOylated mutant of CRMP2 (i.e., CRMP2 K374A) in vivo, reversed SNI-induced 
mechanical allodynia [64]. Because increased NaV1.7 following nerve injury influences the 
hyperexcitability of sensory neurons, which leads to neuropathic pain, here we tested 
whether the “decoy peptide” based on the CRMP2 SUMOylation motif would reverse SNI-
induced mechanical allodynia. The spared nerve injury model resulted in significant 
mechanical and thermal hypersensitivity in both male and female rats (Fig. 10, post-surgery 
group) on day 7 after injury. Spinal delivery of t-CSM (10μg/5μL) resulted in a significant 
long-lasting reversal of both thermal and mechanical hypersensitivity (Fig. 10A, B) that 
François-Moutal et al. Page 9
Pain. Author manuscript; available in PMC 2019 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
returned to the injury baseline by 24 hrs. These results provide proof-of-concept for 
targeting Ubc9-CRMP2 interaction to curb NaV1.7 activity and control nociceptive 
behaviors.
3.9.t-CSM does not affect visceral pain
Although inhibition of tetrodotoxin-sensitive channels was reported to block inflammatory 
and visceral pain [31; 52], pharmacological block of NaV1.7 alone in the viscera may be 
insufficient in targeting chronic visceral pain [36]. Therefore, we tested the potential efficacy 
of t-CSM in the acetic acid-writhing test wherein NaV1.7 is predicted not to contribute. 
Intraperitoneal injection of acetic acid (1%) in female C57BL/6NHsd mice induced 
characteristic writhing behaviors typified by contractions of the abdomen, twisting and 
turning of the trunk, arching of the back and extension of the hind limbs (Fig. 11). In mice 
injected with t-CSM (i.t., 4μg/5μl), 1 hour prior to the acetic acid injection, the number of 
observed writhing events was 35 ± 7 (n=7), which was not different from mice pre-treated 
spinally with 0.1% DMSO (34 ±4 (n=8) (Fig. 11). Thus, t-CSM does not contribute to 
suppression of visceral pain.
3.10. t-CSM peptide does not induce typical motor deficit or sedation in rats
Because the current clinically used medications such as gabapentin result in severe sedation 
in humans, we determined whether our novel t-CSM peptide would result in similar sedative 
or motor impairment (ruling out false positives in pain behavioral tests based on motor reflex 
is of major importance). Naïve male SD rats were used to determine sedation/motor 
impairment so that results are not influenced by “states of injury”. Rats were trained to walk 
on a rotating rod with a maximal cutoff time of 180 seconds prior to administration of 
peptide or vehicle. To ensure availability of the peptide in the spinal cord, we administered 
the drug intrathecally in these experiments. Spinal delivery of t-CSM (20 μg/5 μL i.th.) 
resulted in no motor impairment or sedation (Fig. 12A) since all animals remained on the 
rotating rod until cut off (180 s) over a 24 hours period. In contrast, gabapentin, a drug 
known to produce severe sedation in humans, resulted in a decrease in the ability of naïve 
rats to remain on the rotating rod (data not shown). Motor performance was not affected by 
t-CSM administration in rats with SNI (Fig. 12B). Thus, using t-CSM in vivo is a safe 
strategy to target voltage-gated sodium channel NaV1.7 and reverse chronic pain.
4. Discussion
We examined CRMP2-dependent signaling mechanisms regulating NaV1.7 and peripheral 
pain transmission. We identified a novel interaction between the SUMO conjugating E2 
enzyme Ubc9 and CRMP2 and used rational design to fashion a CRMP2 SUMOylation 
Motif (CSM) “decoy” peptide. We provide in vitro and in vivo evidence that interference of 
the Ubc9-CRMP2 interaction with this peptide reduces CRMP2 SUMOylation, leading to 
reduced NaV1.7 currents, and mitigation of nociception in neuropathic, but not visceral, 
pain.
During the last decade, NaV1.7 emerged as a high-value analgesic target. Mutations in 
SCN9A, the gene encoding NaV1.7, are associated with both lowered as well as heightened 
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sensitivities to pain [2; 18; 38; 82]. Consequently, selectively inhibiting NaV1.7 is likely to 
be critical in modulating pain via pathways involving this channel. NaV1.7-selective 
compounds [13; 49; 85], peptide toxins [90] and neutralizing antibodies [45] cause only 
temporary partial analgesia, and some NaV1.7 gain-of-function mutation patients respond to 
pan-sodium channel blockers [12; 25]. The Waxman group has demonstrated a precision 
medicine approach, using genomics and molecular modeling, to treat pain in a handful of 
humans with gain-of-function mutations in NaV1.7 [7; 29]. Compounds developed by Pfizer 
(PF-0485624 [56]) and Genentech (GX-674, which demonstrated equipotent inhibition of 
NaV1.7 and NaV1.2, and only 4-fold less potency against NaV1.6 [1]) have not progressed 
to clinic. Thus, despite significant investment into NaV1.7 drug development programs, 
there has been only marginal success. We demonstrated that elimination of the CRMP2 
SUMO modification site (i.e., K374) was sufficient to selectively decrease trafficking and 
therefore current density of NaV1.7, but not NaV1.1, 1.3, 1.5, 1.6, 1.8 or 1.9 [10; 19; 21]. 
We reported a 1.78Å resolution X-ray crystal structure of mouse CRMP2, which 
corroborated these findings [20]. The Wood group, using an epitope-tagged NaV1.7 mouse 
identified CRMP2 as part of the NaV1.7 complex in native conditions [41], independently 
confirming our findings. Congruent with these studies, here we identify a novel peptide, t-
CSM, which recapitulates the reduction of sodium influx via NaV1.7. The heptamer peptide 
t-CSM bound to Ubc9 with nanomolar affinity is sufficient for in vitro SUMO-1 
modification by Ubc9. This finding is in line with previous publications demonstrating that 
heptamer peptides, containing the SUMO-1 modification consensus sequence ψKXE, are 
sufficient for in vitro SUMO-1 modification catalyzed by Ubc9 [48; 73]. Thus, these data 
confirm the importance of CRMP2 SUMOylation as a regulator of NaV1.7 activity and 
advance targeting of the Ubc9-CRMP2 interaction as a novel means to achieve regulation of 
NaV1.7, setting the stage for future drug discovery campaigns to find selective CRMP2 
SUMOylation inhibitors.
From a mechanistic viewpoint, targeting NaV1.7-mediated pain behavior takes advantage of 
robust channel expression on nociceptive afferents [17]. This allows reduction of NaV1.7 
trafficking to selectively reduce the activity of ascending pain pathway neurons that promote 
perception of pain. In order to aid successful implementation of this strategy into clinical 
practice, future studies will explore long-term effects of antagonizing NaV1.7 trafficking on 
both ascending and descending pain pathways. Endogenous opioids function as effectors of 
descending pain pathways [80] and a recent study has linked knockout of DRG NaV1.7 
expression and reduction of intracellular DRG sodium concentration to increased 
endogenous opioid mRNA expression [59]. The study utilized opioid receptor antagonists to 
conclude that endogenous opioid production contributes to NaV1.7 knockout-mediated 
congenital insensitivity to pain. Nav-endogenous opioid signaling pathways have not been 
completely elucidated but may permit NaV1.7 trafficking antagonists to engage a secondary 
response via endogenous opioid production. This arrangement could enhance the analgesic 
function of CRMP2 SUMOylation-targeting therapies.
Despite the importance of SUMOylation in regulating diverse biological systems and 
diseases, only a few small-molecule inhibitors of SUMOylation have been reported. These 
include mostly natural products such as ginkgolic acid [27], kerriamycin B [28], 
spectomycin B1, chaetochromin A, and viomellein [35]; however, none of these are 
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commercially available. With respect to diseases, Ubc9 blockers have been utilized in cancer 
therapy because Ubc9 is overexpressed in several cancers [47; 60; 61] and many 
tumorigenesis associated proteins are reported to be SUMOylated [62]. As an example, 
human genome studies provide striking evidence for a link between the impaired 
SUMOylation of a single transcription factor and a predisposition to cancer [3; 92]. All 
hitherto reported strategies are therapeutically impractical because targeting the 
SUMOylation machinery – either E1 or E2 – would generate non-selective antagonists of 
essential biological processes. Our study is the first to design a SUMOylation inhibitor (i.e., 
the t-CSM peptide) against a singular protein-protein interaction (i.e., Ubc9-CRMP2) that is 
expected to allosterically modulate NaV1.7 activity. Because the modification of CRMP2 by 
SUMOylation to selectively regulate NaV1.7 membrane expression is conserved in human 
sensory neurons [19], finding a selective CRMP2 SUMOylation inhibitor would have a high 
likelihood of clinical translation.
Importantly, our approach does not target Ubc9, which is the necessary E2 conjugating 
enzyme for SUMOylation of several protein targets. Ubc9 knockout mice are embryonic 
lethal [68], and global decreases in SUMOylation are implicated in cognitive dysfunction 
[46]. Thus, in an effort to find a selective “druggable” pocket in CRMP2 close to the 
SUMOylation site on residue K374, we generated an in-silico model of CRMP2 with Ubc9-
SUMO (Fig. 13A). The crystal structure of the mammalian guanosine triphosphate 
(GTP)ase-activating protein (RanGAP1), one of the first proteins reported to be covalently 
linked to SUMO [50], with Ubc9–SUMO2 (Protein Data Bank (PDB) ID: 5d2m [8]) was 
used as the starting model in which RanGAP1 was replaced with CRMP2 (PDB ID: 2gse 
[76]). Residue K374 was then used as an anchor to refine the complex using molecular 
minimization with the Schrodinger suite and is in proximity to Ubc9 active site C93 [48] 
(Fig. 13B, C). The identified potential ‘hot spot’ CRMP2 residues include: (i) K23; (ii) 
W366; (iii) V371 of CRMP2, which forms a carbonyl-backbone amide H-bond with A131 
of Ubc9; (iv) M375; (v) E377; (vi) Q379; and (vii) R440 of CRMP2, which forms a salt 
bridge with E132 of Ubc9 (Fig. 13C). It has been shown that single mutations in A131 or 
E132 significantly affect Ubc9’s interaction with target proteins – the tumor suppressor 
protein p53, the ubiquitin-activating enzyme E1B, and promyelocytic leukemia protein – and 
reduce their SUMOylation [48]. Thus, targeting this CRMP2 pocket using in silico docking 
may prove useful in discovering small molecules disrupting CRMP2-Ubc9 interaction in the 
context of pain relief.
That CRMP2 is implicated in neuropathic pain can be surmised from recent work which 
demonstrates that there is a substantial increase in the amount of SUMOylated CRMP2 in 
sensory neurons and spinal cord dorsal horn in rodent models of chronic pain [10; 57; 64; 
78]. This finding is congruent with transcriptomic data demonstrating an enrichment of 
CRMP2 in nociceptors [79], further underscoring the importance of targeting CRMP2 under 
these conditions. Validating the importance of SUMOylation of CRMP2 as a pathologic 
event in chronic pain, we previously observed that transient expression of a SUMO-null 
CRMP2, via spinal administration of plasmid encoding CRMP2 K374A, significantly 
attenuated pain behavior in SNI animals [64]. Here, we extend these findings by using a 
structurally guided, rationally designed CRMP2 SUMO “decoy” peptide that recapitulates 
observations made with the genetic manipulation with the reversal of thermal and tactile 
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hypersensitivity when administered to animals with SNI. Notably, the peptide failed to 
reverse visceral pain, findings consonant with the reported lack of NaV1.7-dependency in 
this acute inflammatory model [36; 52]. These data consolidate the hypothesis that targeting 
CRMP2 SUMOylation to allosterically regulate NaV1.7, and by extension, NaV1.7-
dependent acute, inflammatory, and neuropathic pain is a viable alternative strategy. A 
potential limitation of our study is that not all pain is NaV1.7 dependent; bone cancer pain 
and chemotherapy (i.e., oxaliplatin-evoked) mechanical and cold allodynia occur normally 
in NaV1.7 null mutant mice [58].
Not with standing these limitations, our work suggests that targeting CRMP2 modifications 
can be used to control ion channels implicated in neuropathic pain. Focusing on another 
CRMP2 modification, phosphorylation by cyclin dependent kinase 5 (Cdk5), we 
demonstrated that inhibiting phosphorylation by Cdk5 on residue S522 with (S)-lacosamide, 
an inactive stereoisomer of the clinically used antiepileptic drug (R)-lacosamide (Vimpat®), 
translated into a decrease of calcium influx via presynaptic N-type voltage-gated calcium 
channels [66]. This inhibition resulted in mitigation of thermal hypersensitivity and 
mechanical allodynia in model of postoperative, neuropathic, pain, and cephalic pain [63; 
65]. (S)-lacosamide was also reported to affect NaV1.7-mediated sodium currents in a 
CRMP2 dependent manner, since CRMP2 SUMOylation is dependent on its prior 
phosphorylation by Cdk5 [67]. CRMP2 phosphorylation by Cdk5 at residue S522 plays 
other roles such as that in dendritic development [69]. Consequently, the strategy proposed 
here of disrupting CRMP2 SUMOylation, an event downstream of phosphorylation, may 
represent a more incisive approach for “fine-tuning” CRMP2 modifications to control ion 
channels implicated in pain.
The demonstration of a CRMP2 SUMOylation motif “decoy” peptide in reducing NaV1.7-
mediated sodium influx and reversing SNI-related pain behaviors sets, combined with the 
structural modeling based identification of a pocket harboring CRMP2’s SUMOylation 
motif sets the stage for experimental (ALPHA, MST) and computational (in silico docking) 
screening of ligands/molecules that will biochemically and functionally target CRMP2’s 
SUMOylation to reduce NaV1.7 currents and reverse neuropathic pain.
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Figure 1. CRMP2 co-immunoprecipitates with Ubc9 in CAD cells
Lysates from mouse CAD cells transfected with HA-tagged Ubc9 were immunoprecipitated 
using an antibody against CRMP2. The samples were processed for immunoblotting with 
antibodies against Ubc9 and CRMP2. The blot is representative of 3 individual experiments.
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Figure 2. Ubc9-CRMP2 interaction measured by microscale thermophoresis (MST)
(A) Thermographs of Ubc9-GST (0.003 - 100 μM) binding to increasing concentrations of 
NT-647 labeled CRMP2 altered thermodiffusion providing well-defined curves. (B) 
Thermographs of GST (0.007 to 120 μM) provided no thermodiffusion of NT-647 labeled 
CRMP2. The grey bar (at ~2 s) represents the steady-state time point at which the MST 
measurements were analyzed for the graphs shown in panel C. (C) MST values were used to 
determine dissociation constant for binding of Ubc9 to CRMP2. The data were fitted as 
described in the Methods section yielding an apparent Kd of 12.2 ± 2.7 μM (r2 = 0.98). ATP 
(1mM) had no effect on the dissociation constant (Kd = 7.6 ± 2.9 μM, r2 = 0.91). CaCl2 or 
MgCl2 (200 mM) had no significant effect on the Kd values (26 ± 1.7 μM, r2 = 0.98 and 25.5 
± 3.0 μM, r2 = 0.98, respectively). No association could be detected between GST and 
CRMP2, thus no binding curve was extractable. Data is presented as means ± SEM (n=3). 
Some error bars are smaller than the symbols.
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Figure 3. Structure guided rational design of a CRMP2 SUMOylation Motif (CSM) “decoy” 
peptide
(A) Surface representation of CRMP2 monomer (subunit A, PDB ID: 5uqc [20]) with K374 
(spheres) within the GKMDENQ peptide shown in CPK coloring (green, carbon; red, 
oxygen; blue, nitrogen; yellow sulfur). Close-up view of GKMDENQ peptide in surface (B) 
and cartoon (C) representations. A CRMP2 heptamer peptide fused with the transduction 
domain of the HIV-1 tat protein was designed to disrupt Ubc9-CRMP2 interaction and 
designated as tat-CRMP2 SUMOylation Motif (t-CSM), it includes the residue K374 (red) 
and the surrounding amino acids. (D) Thermographs of NT-647 labeled Ubc9 binding to 
various concentrations of t-CSM were used to determine dissociation constant for binding of 
t-CSM peptide to labelled Ubc9, apparent Kd = 0.4 ±0.1 μM. The data was fitted using the 
Hill method (r2 = 0.96).
François-Moutal et al. Page 22
Pain. Author manuscript; available in PMC 2019 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. t-CSM peptide disrupts the Ubc9-CRMP2 interaction as determined via ALPHA
(A) ALPHA assay schematic. The ALPHA assay signal is generated following the transfer 
of singlet oxygen between nickel-chelate donor beads (CRMP2-His) and a glutathione 
acceptor bead chelated to Ubc9-GST. (B) Black and white image of Coomassie-stained gel 
of 1 and 5 μg of purified CRMP2-His and Ubc9-GST (arrowheads). (C) Steady state binding 
of 200 nM Ubc9-GST to 800 nM CRMP2-His over 24 hr with a stable signal over ~18 hr. In 
presence of both donor and acceptor beads, the ALPHA signal was always at least 500 times 
higher than the signal generated in absence of acceptor beads or without any beads (negative 
controls). For this ALPHA experiment (performed in triplicate), the signal/background ratio 
was ~50 with a Z’ factor (index for quality control) of 0.71. (D) ALPHA signal generated by 
the binding of CRMP2 with ranging concentration of Ubc9. The data was fitted using the 
Hill method (r2 = 0.96). The apparent Kd is 0.8 ± 0.2μM. No association between CRMP2 
and Ubc9 could be detected in presence of 1 μM t-CSM. Data is presented as means ± SEM 
(n=3). Error bars are smaller than the symbols.
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Figure 5. t-CSM peptide disrupts the Ubc9-CRMP2 interaction
Microscale thermophoresis (MST) analyses was used to determine the binding between 
Ubc9-GST (0.003 – 100 μM) and NT-647 labeled CRMP2 (50 nM) in the absence (DMSO, 
0.1%) or presence of increasing concentrations of t-CSM peptide. MST data were fitted as 
described in the Methods section. Ubc9-CRMP2 binding was reduced by t-CSM in a 
concentration-dependent manner: t-CSM, at 2.5 and 5μM, reduced the binding of Ubc9-GST 
to CRMP2 (Kd = 80 ± 14 μM and 137 ± 14 μM, respectively). No association could be 
detected between CRMP2 and Ubc9 at 10 μM and 20μM of t-CSM. Data is presented as 
means ± SEM (n=3). Error bars are smaller than the symbols.
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Figure 6. t-CSM blocks SUMOylation of CRMP2 in CAD cells
(A) Immunoprecipitates (IP) enriched with a SUMO1 antibody from CRMP2- (treated with 
0.1% DMSO or 20 μM t-CSM peptide overnight) and CRMP2-K374A- (negative control) 
expressing catecholamine A differentiated (CAD) cells probed with an anti-CRMP2 
polyclonal antibody. The leftmost lane (top panel) shows a negative control where anti-
SUMO1 antibody was omitted. Lysates of cells are shown (bottom panel) to demonstrate 
equal amounts of total CRMP2. Representative Western blots show a significant reduction of 
CRMP2 SUMOylation with t-CSM peptide or in cells expressing a SUMO-incompetent 
CRMP2. (B) Bar graph showing the quantitative analysis of relative SUMOylated CRMP2 
levels for the indicated conditions. Mean ± SEM, * p < 0.05 compared to SUMOylated 
CRMP2 level in DMSO treated cells, one-way ANOVA with Tukey’s post-hoc test; n=4.
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Figure 7. t-CSM decreases Na+ current density in CAD cells
(A) Voltage protocol for current-voltage relationship: Na+ currents were evoked by 5-ms 
voltage steps from −70 to +60 mV in 5-mV increments from a holding potential of −80 mV. 
(B) Na+ current traces were measured from vehicle treated (black) or 20 μM t-CSM treated 
(red) neurons. (C) Summary current density in the absence or presence of t-CSM 
(normalized to 34.2 ± 4.7 pF and 28.6 ± 3.3 pF, respectively). Incubation of CAD cells with 
t-CSM produced a marked decreased in current density. (*p < 0.05, Student’s t-test, n = 6 
cells). (D) Representative Boltzmann fits for activation and steady-state inactivation for 
NaV1.7. No significant differences were detected in half-maximal voltage or slope 
properties of fast inactivation or activation. Data show means ±SEM (n=6).
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Figure 8. Peptide t-CSM, tetrodotoxin (TTX), and Protox attenuate ouabain-induced increase in 
cytosolic Na+ ([Na+]c) in primary sensory neurons
Neurons loaded with SBFI-AM, a Na+ sensitive fluorescent dye, were treated with 1 mM 
ouabain alone (A) or in combination with 1μM TTX (C) or 10μM Protox (D), as indicated. 
(B) Neurons were pre-incubated with 10μM t-CSM for 12 hours, and then loaded with 
SBFI-AM and taken into the experiment. t-CSM (10μM) was present in the medium during 
SBFI loading and then during the experiment. (E) Statistical analysis of ouabain-induced 
changes in [Na+]c. The ouabain-induced changes in [Na+]c over time were quantified by 
calculating the area under the curve (AUC). The AUC was calculated for 1200 seconds 
following application of ouabain and other drugs. Data are means ± SEM, *p<0.05, 
**p<0.01. n=5 independent experiments from the indicated number of total cells.
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Figure 9. t-CSM restricts NaV1.7 membrane localization in DRG sensory neurons
After an overnight treatment with either 0.1% DMSO or 20 μM t-CSM, Nav1.7 membrane 
localization was detected in sensory neurons. (A) Representative fluorescent micrographs of 
DRG neurons immunostained with an antibody against an extracellular epitope for NaV1.7. 
Fluorescent signal can be detected when NaV1.7 was localized at the plasma membrane in 
live DRG neurons. (B) Bar graph showing the relative surface NaV1.7 signal compared to 
the levels in the 0.1% DMSO-treated cells. Fluorescent signal from (A) was quantified and 
normalized to the area of the cell of interest. Treating the cells with 20 μM of t-CSM 
resulted in decreased membrane localization of NaV1.7. Mean ± SEM, *p<0.05, Student’s t-
test (n=30 to 45 cells).
François-Moutal et al. Page 28
Pain. Author manuscript; available in PMC 2019 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 10. t-CSM peptide reverses spared nerve injury (SNI) chronic pain
Rats developed mechanical allodynia (A) and thermal hyperalgesia (B) 7 days after SNI but 
not with after a sham injury. Intrathecal injection (black arrow) of t-CSM (10μg/5μl), but not 
vehicle (0.01% DMSO), significantly reversed the mechanical allodynia, measured by paw 
withdrawal threshold (in grams), and thermal hyperalgesia, as measure by paw withdrawal 
latency (in sec), for at least 6 hours after injection (n=6; *p< 0.05 vs. pre-injection baseline, 
2-way ANOVA, post hoc Student-Neuman-Kuels). Brown and green symbols represent 
female SNI rats (n=6 each) treated with vehicle or t-CSM, respectively.
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Figure 11. t-CSM peptide does not affect visceral pain
Writhing characterized by abdominal stretching combined with a exaggerated extension of 
the hind limbs was induced by intraperitoneal injection of acetic acid in female mice. t-CSM 
peptide was administered i.t. 60 min prior the acetic acid injection. The scatter plot and bar 
graph represents the mean ± SEM of number of writhes obtained in 7–8 mice. No significant 
differences were detected between the conditions (Wilcoxon–Mann–Whitney nonparametric 
test).
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Figure 12. The intrathecal administration of t-CSM did not result in significant deficit in motor 
coordination as tested using the rotarod performance test
t-CSM (20 μg/5 μL, i.th.) was evaluated for motor deficits using the rotarod performance test 
using naïve (A) or SNI (B) rats. Vehicle treated animals and t-CSM treated animals 
remained on the rotarod for an average of 180 ± 0 seconds over a 24 hours period (p>0.01, 
two-way ANOVA, n=6–8). t-CSM did not affect motor performance at any time point 
measured in the SNI rats (p>0.01, two-way ANOVA, n=6–8).
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Figure 13. Mapping the interface between CRMP2 and Ubc9
(A) Ribbon diagram of in silico model of CRMP2 (PDB ID: 2gse [76]) in gray with Ubc9 in 
white and SUMO-2 in black (PDB ID: 5d2m [8]). (B) View of CRMP2 K374 near the active 
site cysteine (C93) of Ubc9. (C) Hotspot residues in CRMP2 (carbon atoms in magenta) and 
Ubc9 (carbon atoms in teal). Dashed line indicates potential salt-bridge interaction between 
R440 and E132.
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